Patient-Specific Single-Cell Transcriptomics for Targeted Therapies

Developing effective personalized treatment plans requires a deep understanding of a patient's unique cellular heterogeneity. Parse Biosciences Evercode technology enables high-throughput single-cell RNA sequencing of patient biopsies to identify rare, drug-resistant cellular subpopulations. By mapping individual cellular responses to various therapeutic agents, clinicians can uncover precise mechanisms of action and predict clinical outcomes.

Learn More
Imperial
Cell

3D Bioprinting of Patient-Derived Tumor Model

Developing tailored oncology treatments requires highly predictive in vitro models that replicate individual patient pathology. Using CELLINK's precise 3D bioprinting platforms, scientists can fabricate complex, patient-derived tumor models directly from primary clinical biopsies. These robust multicellular constructs accurately capture the unique heterogeneity and architecture of a specific patient's microenvironment.

Learn More

Spatial Phenotyping of Tumor Microenvironments for Immunotherapy

Predicting patient response to immunotherapies requires analyzing not just cell types, but their exact spatial orientation within native tissues. Bruker’s spatial biology platforms deliver high-plex in situ analysis of patient biopsy samples, mapping hundreds of protein biomarkers simultaneously at subcellular resolution. This deep phenotypic mapping reveals the precise spatial relationships between immune cells and tumor boundaries.

Learn More
Bruker

Do you have any question about our services?